We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q3 Potential of Integer (ITGR): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Integer (ITGR - Free Report) to post quarterly earnings of $1.36 per share in its upcoming report, which indicates a year-over-year increase of 7.1%. Revenues are expected to be $443.19 million, up 9.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Integer metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Sales- Non-Medical' will reach $8.44 million. The estimate suggests a change of -4% year over year.
The consensus among analysts is that 'Sales- Total Medical Sales' will reach $437.05 million. The estimate points to a change of +10.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' should arrive at $21.85 million. The estimate indicates a change of -3.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Sales- Medical Sales- Cardio & Vascular' should come in at $240.48 million. The estimate indicates a change of +12.4% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' of $174.72 million. The estimate indicates a year-over-year change of +9.7%.
Integer shares have witnessed a change of -1.2% in the past month, in contrast to the Zacks S&P 500 composite's +2.7% move. With a Zacks Rank #4 (Sell), ITGR is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q3 Potential of Integer (ITGR): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect Integer (ITGR - Free Report) to post quarterly earnings of $1.36 per share in its upcoming report, which indicates a year-over-year increase of 7.1%. Revenues are expected to be $443.19 million, up 9.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Integer metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Sales- Non-Medical' will reach $8.44 million. The estimate suggests a change of -4% year over year.
The consensus among analysts is that 'Sales- Total Medical Sales' will reach $437.05 million. The estimate points to a change of +10.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' should arrive at $21.85 million. The estimate indicates a change of -3.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Sales- Medical Sales- Cardio & Vascular' should come in at $240.48 million. The estimate indicates a change of +12.4% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' of $174.72 million. The estimate indicates a year-over-year change of +9.7%.
View all Key Company Metrics for Integer here>>>
Integer shares have witnessed a change of -1.2% in the past month, in contrast to the Zacks S&P 500 composite's +2.7% move. With a Zacks Rank #4 (Sell), ITGR is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>